Bristol-Myers
Squibb BMY today announced that the National Institute for
Health and Care Excellence (NICE) has recommended Daklinza
(daclatasvir) in England and Wales for the treatment of adult
patients with chronic hepatitis C virus (HCV) infection. Specifically,
NICE recommended Daklinza, an oral, once-daily medication used in
combination with other agents, to treat certain patients with HCV
genotypes 1, 3 and 4. Approximately 214,000 people in the UK
are thought to have chronic HCV, and roughly 100,000 of those patients
are estimated to have genotype 3, a difficult-to-treat and often
aggressive form of chronic HCV.
"It is a challenge to treat patients with hepatitis C virus infection,
including the
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in